Review article: the current pharmacological therapies for hepatic encephalopathy
Effective treatment options for hepatic encephalopathy are limited. Based on the principle that intestinal‐derived ammonia contributes to the pathogenesis of hepatic encephalopathy, current therapeutic approaches are directed at reducing bacterial production of ammonia and enhancing its elimination....
Saved in:
| Published in | Alimentary pharmacology & therapeutics Vol. 25; no. s1; pp. 23 - 31 |
|---|---|
| Main Author | |
| Format | Journal Article |
| Language | English |
| Published |
Oxford, UK
Blackwell Publishing Ltd
01.02.2007
|
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Effective treatment options for hepatic encephalopathy are limited. Based on the principle that intestinal‐derived ammonia contributes to the pathogenesis of hepatic encephalopathy, current therapeutic approaches are directed at reducing bacterial production of ammonia and enhancing its elimination.
Non‐absorbable disaccharides are first‐line therapy for hepatic encephalopathy, but published clinical studies evaluating their safety and efficacy are limited. Alternative therapies such as benzodiazepine receptor antagonists, branched‐chain amino acids, and l‐ornithine‐l‐aspartate also have limited clinical data supporting their use.
Studies of antibiotics indicate that they are effective in the treatment of hepatic encephalopathy, but adverse effects and concerns about long‐term safety have limited the widespread use of most.
Rifaximin is a minimally absorbed antibiotic that concentrates in the gastrointestinal tract and is excreted mostly unchanged in faeces. It has been studied extensively in the treatment of hepatic encephalopathy and appears to confer therapeutic benefits greater than those of placebo and non‐absorbable disaccharides and at least comparable with those of systemic antibiotics. Rifaximin was also well tolerated in patients with hepatic encephalopathy and is not associated with clinical drug interactions or clinically relevant bacterial antibiotic resistance.
In conclusion, non‐absorbed antibiotics such as rifaximin offer a favourable benefit–risk ratio in the treatment of hepatic encephalopathy and may help to improve patient outcomes. |
|---|---|
| AbstractList | Effective treatment options for hepatic encephalopathy are limited. Based on the principle that intestinal-derived ammonia contributes to the pathogenesis of hepatic encephalopathy, current therapeutic approaches are directed at reducing bacterial production of ammonia and enhancing its elimination. Non-absorbable disaccharides are first-line therapy for hepatic encephalopathy, but published clinical studies evaluating their safety and efficacy are limited. Alternative therapies such as benzodiazepine receptor antagonists, branched-chain amino acids, and l-ornithine-l-aspartate also have limited clinical data supporting their use. Studies of antibiotics indicate that they are effective in the treatment of hepatic encephalopathy, but adverse effects and concerns about long-term safety have limited the widespread use of most. Rifaximin is a minimally absorbed antibiotic that concentrates in the gastrointestinal tract and is excreted mostly unchanged in faeces. It has been studied extensively in the treatment of hepatic encephalopathy and appears to confer therapeutic benefits greater than those of placebo and non-absorbable disaccharides and at least comparable with those of systemic antibiotics. Rifaximin was also well tolerated in patients with hepatic encephalopathy and is not associated with clinical drug interactions or clinically relevant bacterial antibiotic resistance. In conclusion, non-absorbed antibiotics such as rifaximin offer a favourable benefit-risk ratio in the treatment of hepatic encephalopathy and may help to improve patient outcomes. Effective treatment options for hepatic encephalopathy are limited. Based on the principle that intestinal‐derived ammonia contributes to the pathogenesis of hepatic encephalopathy, current therapeutic approaches are directed at reducing bacterial production of ammonia and enhancing its elimination. Non‐absorbable disaccharides are first‐line therapy for hepatic encephalopathy, but published clinical studies evaluating their safety and efficacy are limited. Alternative therapies such as benzodiazepine receptor antagonists, branched‐chain amino acids, and l ‐ornithine‐ l ‐aspartate also have limited clinical data supporting their use. Studies of antibiotics indicate that they are effective in the treatment of hepatic encephalopathy, but adverse effects and concerns about long‐term safety have limited the widespread use of most. Rifaximin is a minimally absorbed antibiotic that concentrates in the gastrointestinal tract and is excreted mostly unchanged in faeces. It has been studied extensively in the treatment of hepatic encephalopathy and appears to confer therapeutic benefits greater than those of placebo and non‐absorbable disaccharides and at least comparable with those of systemic antibiotics. Rifaximin was also well tolerated in patients with hepatic encephalopathy and is not associated with clinical drug interactions or clinically relevant bacterial antibiotic resistance. In conclusion, non‐absorbed antibiotics such as rifaximin offer a favourable benefit–risk ratio in the treatment of hepatic encephalopathy and may help to improve patient outcomes. AbstractEffective treatment options for hepatic encephalopathy are limited. Based on the principle that intestinal-derived ammonia contributes to the pathogenesis of hepatic encephalopathy, current therapeutic approaches are directed at reducing bacterial production of ammonia and enhancing its elimination.Non-absorbable disaccharides are first-line therapy for hepatic encephalopathy, but published clinical studies evaluating their safety and efficacy are limited. Alternative therapies such as benzodiazepine receptor antagonists, branched-chain amino acids, and l-ornithine-l-aspartate also have limited clinical data supporting their use.Studies of antibiotics indicate that they are effective in the treatment of hepatic encephalopathy, but adverse effects and concerns about long-term safety have limited the widespread use of most.Rifaximin is a minimally absorbed antibiotic that concentrates in the gastrointestinal tract and is excreted mostly unchanged in faeces. It has been studied extensively in the treatment of hepatic encephalopathy and appears to confer therapeutic benefits greater than those of placebo and non-absorbable disaccharides and at least comparable with those of systemic antibiotics. Rifaximin was also well tolerated in patients with hepatic encephalopathy and is not associated with clinical drug interactions or clinically relevant bacterial antibiotic resistance.In conclusion, non-absorbed antibiotics such as rifaximin offer a favourable benefit-risk ratio in the treatment of hepatic encephalopathy and may help to improve patient outcomes. Effective treatment options for hepatic encephalopathy are limited. Based on the principle that intestinal‐derived ammonia contributes to the pathogenesis of hepatic encephalopathy, current therapeutic approaches are directed at reducing bacterial production of ammonia and enhancing its elimination. Non‐absorbable disaccharides are first‐line therapy for hepatic encephalopathy, but published clinical studies evaluating their safety and efficacy are limited. Alternative therapies such as benzodiazepine receptor antagonists, branched‐chain amino acids, and l‐ornithine‐l‐aspartate also have limited clinical data supporting their use. Studies of antibiotics indicate that they are effective in the treatment of hepatic encephalopathy, but adverse effects and concerns about long‐term safety have limited the widespread use of most. Rifaximin is a minimally absorbed antibiotic that concentrates in the gastrointestinal tract and is excreted mostly unchanged in faeces. It has been studied extensively in the treatment of hepatic encephalopathy and appears to confer therapeutic benefits greater than those of placebo and non‐absorbable disaccharides and at least comparable with those of systemic antibiotics. Rifaximin was also well tolerated in patients with hepatic encephalopathy and is not associated with clinical drug interactions or clinically relevant bacterial antibiotic resistance. In conclusion, non‐absorbed antibiotics such as rifaximin offer a favourable benefit–risk ratio in the treatment of hepatic encephalopathy and may help to improve patient outcomes. |
| Author | BASS, N. M. |
| Author_xml | – sequence: 1 givenname: N. M. surname: BASS fullname: BASS, N. M. |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/17295849$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNkMtKAzEUhoMo2qqvILNyN2PuyQguRLyBoEhdhzSecabMzWRq27c3YwsuNZvkcL7_D3xTtN92LSCUEJyReC4WGVFcppJxmlGMZYYZJTpb76EJYVKkFDO5jyaYyjylmrAjNA1hgSOpMD1ER0TRXGieT9DLK3xVsEqsHypXw2UylJC4pffQDklfWt9Y19XdR-VsPe687SsISdH5pITexlACrYNI1l0cy80JOihsHeB0dx-jt7vb2c1D-vR8_3hz_ZQ6lmudMqdy4awShZUCBHnnuQZlrdBMSOuoZpYzJYVSMsdaCVZIbnMh-FxhTefAjtH5trf33ecSwmCaKjioa9tCtwwmxjDjTP4JUsw5FlhFUG9B57sQPBSm91Vj_cYQbEbtZmFG7WbUbkbt5ke7Wcfo2e6P5byB99_gznMErrbAqqph8-9ic_0yG1_sG_RckhM |
| CitedBy_id | crossref_primary_10_1097_MEG_0b013e3283417567 crossref_primary_10_5056_jnm_2011_17_4_427 crossref_primary_10_1097_MCG_0000000000001040 crossref_primary_10_1590_1806_9282_62_03_243 crossref_primary_10_1016_j_jphotobiol_2017_05_005 crossref_primary_10_1016_S1665_2681_19_31604_7 crossref_primary_10_12968_hmed_2012_73_2_79 crossref_primary_10_1016_j_coph_2012_09_010 crossref_primary_10_1002_14651858_CD012334_pub2 crossref_primary_10_1016_S0025_6196_11_60837_9 crossref_primary_10_1056_NEJMoa0907893 crossref_primary_10_1097_MPG_0000000000002973 crossref_primary_10_4065_83_2_165 crossref_primary_10_1111_j_1365_2036_2009_04211_x crossref_primary_10_4161_gmic_29417 crossref_primary_10_1016_j_tice_2013_06_001 crossref_primary_10_1111_hepr_13045 crossref_primary_10_1016_j_aohep_2022_100757 crossref_primary_10_4254_wjh_v7_i30_2940 crossref_primary_10_1177_0897190008328693 crossref_primary_10_1016_j_psym_2016_03_006 crossref_primary_10_1111_j_1365_2982_2012_01906_x crossref_primary_10_2165_10898630_000000000_00000 crossref_primary_10_3402_mehd_v23i0_19007 crossref_primary_10_1016_j_neurobiolaging_2010_09_018 crossref_primary_10_1111_j_1365_2036_2011_04590_x crossref_primary_10_1111_j_1440_1746_2010_06596_x crossref_primary_10_1111_j_1746_6342_2006_03216_x crossref_primary_10_1097_MCG_0b013e318169c44e crossref_primary_10_1177_875512250902500207 crossref_primary_10_1016_j_cld_2012_03_009 crossref_primary_10_12968_bjon_2017_26_13_724 crossref_primary_10_14260_Jemds_2017_1153 crossref_primary_10_1016_j_cld_2011_12_007 |
| Cites_doi | 10.1016/S0168-8278(98)80237-7 10.1016/S0011-393X(05)80681-2 10.1345/aph.1E407 10.3810/pgm.2001.02.850 10.1016/S0168-8278(99)80144-5 10.1007/978-1-4684-5826-8_13 10.1136/gut.23.1.1 10.1016/0016-5085(79)90399-8 10.1185/03007999309111539 10.3349/ymj.2005.46.3.399 10.1016/S0011-393X(05)80433-3 10.1002/hep.510250609 10.1007/BF01295920 10.1056/NEJM199708143370707 10.1128/AAC.44.8.2205-2206.2000 10.3109/00365528708991867 10.1016/0168-8278(90)90103-X 10.1002/hep.1840040218 10.1007/978-1-4615-1989-8_13 10.3748/wjg.v11.i45.7197 10.1016/0002-9343(79)90649-1 10.1185/03007999709113333 10.1093/qjmed/hcg110 10.1002/hep.1840160123 10.1016/S1542-3565(04)00667-6 10.1185/03007999509111552 10.1177/0148607196020002159 10.1016/S0168-8278(02)00350-1 10.1136/bmj.38048.506134.EE 10.1016/S0016-5085(77)80135-2 10.1016/0016-5085(89)91517-5 10.1016/S0140-6736(79)92119-6 10.1016/j.jinf.2004.05.019 10.1111/j.1572-0241.2001.03964.x 10.1016/j.curtheres.2004.10.002 10.1097/00042737-200012020-00012 10.1002/hep.510280212 |
| ContentType | Journal Article |
| DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION 7QL 7TK C1K 7X8 |
| DOI | 10.1111/j.1746-6342.2006.03218.x |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef Bacteriology Abstracts (Microbiology B) Neurosciences Abstracts Environmental Sciences and Pollution Management MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef Neurosciences Abstracts Bacteriology Abstracts (Microbiology B) Environmental Sciences and Pollution Management MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic CrossRef MEDLINE Neurosciences Abstracts |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1365-2036 |
| EndPage | 31 |
| ExternalDocumentID | 10_1111_j_1746_6342_2006_03218_x 17295849 APT3218 |
| Genre | reviewArticle Research Support, Non-U.S. Gov't Journal Article Review |
| GroupedDBID | --- .3N .GA .GJ .Y3 05W 0R~ 10A 1OB 1OC 23M 24P 31~ 33P 36B 3SF 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5HH 5LA 5VS 66C 6J9 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAESR AAEVG AAHHS AAKAS AANLZ AAONW AASGY AAXRX AAZKR ABCQN ABCUV ABDBF ABEML ABJNI ABOCM ABPVW ABQWH ABXGK ACAHQ ACBWZ ACCFJ ACCZN ACGFS ACGOF ACMXC ACPOU ACPRK ACSCC ACXBN ACXQS ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADOZA ADXAS ADZCM ADZMN ADZOD AEEZP AEGXH AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFEBI AFFPM AFGKR AFPWT AFRAH AFZJQ AHBTC AHEFC AIACR AITYG AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN AMBMR AMYDB ASPBG ATUGU AVWKF AZBYB AZFZN AZVAB BAFTC BAWUL BDRZF BFHJK BHBCM BMXJE BROTX BRXPI BY8 C45 CAG COF D-6 D-7 D-E D-F DC6 DCZOG DIK DPXWK DR2 DRFUL DRMAN DRSTM DTERQ E3Z EAD EAP EAS EBC EBD EBS EBX EJD EMB EMK EMOBN EST ESX EX3 F00 F01 F04 F5P FEDTE FIJ FUBAC FZ0 G-S G.N GODZA GX1 H.X HF~ HGLYW HVGLF HZI HZ~ IHE IPNFZ IX1 J0M K48 KBYEO LATKE LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES MEWTI MK0 MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ O66 O9- OIG OK1 OVD P2P P2W P2X P2Z P4B P4D P6G PALCI Q.N Q11 QB0 Q~Q R.K RIWAO RJQFR ROL RX1 SAMSI SUPJJ SV3 TEORI TR2 TUS UB1 V8K V9Y W8V W99 WBKPD WH7 WHWMO WIH WIJ WIK WIN WOHZO WOW WQJ WRC WUP WVDHM WXI WXSBR XG1 YOC ZZTAW ~IA ~WT CGR CUY CVF ECM EIF NPM AAMNL AAYXX ACRPL ACYXJ CITATION 7QL 7TK C1K 7X8 |
| ID | FETCH-LOGICAL-c3988-3c795ca75fa65e51d498e7aa58356ac283a43765776908753f64a9554b7082be3 |
| IEDL.DBID | DR2 |
| ISSN | 0269-2813 |
| IngestDate | Wed Dec 04 07:07:43 EST 2024 Wed Dec 04 11:36:55 EST 2024 Fri Dec 06 05:17:04 EST 2024 Sat Sep 28 07:55:55 EDT 2024 Sat Aug 24 00:40:45 EDT 2024 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | s1 |
| Language | English |
| License | http://onlinelibrary.wiley.com/termsAndConditions#vor |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c3988-3c795ca75fa65e51d498e7aa58356ac283a43765776908753f64a9554b7082be3 |
| Notes | NMB has received honoraria as a speaker and consultant for Salix Pharmaceuticals, Inc. ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Article-2 ObjectType-Feature-3 ObjectType-Review-1 |
| PMID | 17295849 |
| PQID | 20440507 |
| PQPubID | 23462 |
| PageCount | 9 |
| ParticipantIDs | proquest_miscellaneous_69003436 proquest_miscellaneous_20440507 crossref_primary_10_1111_j_1746_6342_2006_03218_x pubmed_primary_17295849 wiley_primary_10_1111_j_1746_6342_2006_03218_x_APT3218 |
| PublicationCentury | 2000 |
| PublicationDate | February 2007 2007-Feb 2007-02-00 20070201 |
| PublicationDateYYYYMMDD | 2007-02-01 |
| PublicationDate_xml | – month: 02 year: 2007 text: February 2007 |
| PublicationDecade | 2000 |
| PublicationPlace | Oxford, UK |
| PublicationPlace_xml | – name: Oxford, UK – name: England |
| PublicationTitle | Alimentary pharmacology & therapeutics |
| PublicationTitleAlternate | Aliment Pharmacol Ther |
| PublicationYear | 2007 |
| Publisher | Blackwell Publishing Ltd |
| Publisher_xml | – name: Blackwell Publishing Ltd |
| References | 2004; 65 1990; 11 2000; 44 2006; 130 1992; 16 2004; 328 2001; 109 2003; 96 1979; 76 1993; 4 1992; 52 1982; 23 1979; 67 1993; 38 2001 1978; 23 2000; 12 1997; 13 1977; 72 2003; 49 1979; 2 1985; 11 2005; 39 2001; 96 1996; 20 2002; 36 1966; 1 1998; 28 1997; 337 2004; 40 1995; 13 1997; 25 1992; 39 2003; 38 2005 2004 1996; 91 2005; 46 1987; 22 1993; 13 1989; 97 1994; 368 1991; 23 1984; 36 1984; 4 1993; 54 1999; 30 1994; 18 2005; 3 2005; 50 2005; 11 1990; 272 e_1_2_8_28_2 e_1_2_8_49_2 e_1_2_8_24_2 e_1_2_8_45_2 Lata J (e_1_2_8_39_2) 2002; 36 e_1_2_8_26_2 e_1_2_8_47_2 Blanc P (e_1_2_8_15_2) 1994; 18 e_1_2_8_3_2 e_1_2_8_5_2 e_1_2_8_7_2 e_1_2_8_20_2 e_1_2_8_22_2 e_1_2_8_43_2 Loguercio C (e_1_2_8_38_2) 2003; 49 e_1_2_8_17_2 Giacomo F (e_1_2_8_30_2) 1993; 4 e_1_2_8_19_2 e_1_2_8_13_2 e_1_2_8_36_2 e_1_2_8_57_2 Conn HO (e_1_2_8_9_2) 1977; 72 Di Piazza S (e_1_2_8_32_2) 1991; 23 De Marco F (e_1_2_8_35_2) 1984; 36 e_1_2_8_55_2 e_1_2_8_11_2 e_1_2_8_53_2 Massa P (e_1_2_8_29_2) 1993; 4 e_1_2_8_51_2 e_1_2_8_27_2 Strauss E (e_1_2_8_14_2) 1992; 39 e_1_2_8_23_2 e_1_2_8_25_2 e_1_2_8_48_2 e_1_2_8_2_2 Leevy CB (e_1_2_8_41_2) e_1_2_8_6_2 Chalasani N (e_1_2_8_46_2) 1996; 91 e_1_2_8_8_2 e_1_2_8_44_2 Uribe M (e_1_2_8_50_2) 1979; 76 e_1_2_8_40_2 e_1_2_8_16_2 e_1_2_8_18_2 (e_1_2_8_54_2) 2004 Bass NM (e_1_2_8_4_2) 2004; 40 e_1_2_8_37_2 e_1_2_8_56_2 Pedretti G (e_1_2_8_31_2) 1991; 23 Spiegel BM (e_1_2_8_42_2) 2006; 130 (e_1_2_8_21_2) 2005 Bircher J (e_1_2_8_12_2) 1966; 1 Atterbury CE (e_1_2_8_10_2) 1978 e_1_2_8_33_2 e_1_2_8_52_2 Testa R (e_1_2_8_34_2) 1985; 11 |
| References_xml | – volume: 72 start-page: 573 year: 1977 end-page: 83 article-title: Comparison of lactulose and neomycin in the treatment of chronic portal‐systemic encephalopathy publication-title: Gastroenterology – volume: 30 start-page: 890 year: 1999 end-page: 5 article-title: Prognostic significance of hepatic encephalopathy in patients with cirrhosis publication-title: J Hepatol – year: 2005 – volume: 44 start-page: 2205 year: 2000 end-page: 6 article-title: In vitro activity and fecal concentration of rifaximin after oral administration publication-title: Antimicrob Agents Chemother – article-title: Hospitalizations during the use of rifaximin versus lactulose for the treatment of hepatic encephalopathy publication-title: Dig Dis Sci – volume: 49 start-page: 53 year: 2003 end-page: 62 article-title: Cyclic treatment of chronic hepatic encephalopathy with rifaximin: results of a double‐blind clinical study publication-title: Minerva Gastroenterol Dietol – volume: 272 start-page: 197 year: 1990 end-page: 208 article-title: Effect of L‐carnitine upon ammonia tolerance test in cirrhotic patients publication-title: Adv Exp Med Biol – volume: 22 start-page: 117 year: 1987 end-page: 23 article-title: Metronidazole pharmacokinetics in patients with hepatic encephalopathy publication-title: Scand J Gastroenterol – volume: 11 start-page: 133 year: 1990 end-page: 41 article-title: Branched chain amino acids in the management of chronic liver disease. Facts and fantasies publication-title: J Hepatol – volume: 109 start-page: 52 year: 2001 end-page: 70 article-title: Hepatic encephalopathy: metabolic consequence of cirrhosis often is reversible publication-title: Postgrad Med – volume: 11 start-page: 387 year: 1985 end-page: 92 article-title: A non‐absorbable rifamycin for treatment of hepatic encephalopathy publication-title: Drugs Exp Clin Res – volume: 23 start-page: 1 year: 1982 end-page: 7 article-title: Treatment of hepatic encephalopathy with metronidazole publication-title: Gut – volume: 91 start-page: 1266 year: 1996 end-page: 8 article-title: Severe recurrent hepatic encephalopathy that responded to oral branched chain amino acids publication-title: Am J Gastroenterol – volume: 368 start-page: 125 year: 1994 end-page: 34 article-title: Neomycin reduces the intestinal production of ammonia from glutamine publication-title: Adv Exp Med Biol – volume: 3 start-page: 184 year: 2005 end-page: 191 article-title: A randomized controlled trial of acarbose in hepatic encephalopathy publication-title: Clin Gastroenterol Hepatol – volume: 36 start-page: 668 year: 1984 end-page: 74 article-title: Rifaximin in collateral treatment of portal‐systemic encephalopathy: a preliminary report publication-title: Curr Ther Res Clin Exp – volume: 16 start-page: 138 year: 1992 end-page: 44 article-title: Sodium benzoate in the treatment of acute hepatic encephalopathy: a double‐blind randomized trial publication-title: Hepatology – volume: 52 start-page: 34 year: 1992 end-page: 9 article-title: Effect of rifaximin and paromomycin in the treatment of portal‐systemic encephalopathy publication-title: Curr Ther Res Clin Exp – volume: 97 start-page: 1033 year: 1989 end-page: 42 article-title: Parenteral nutrition with branched‐chain amino acids in hepatic encephalopathy. A meta‐analysis publication-title: Gastroenterology – volume: 23 start-page: 175 year: 1991 end-page: 8 article-title: Rifaximin versus neomycin on hyperammoniemia in chronic portal systemic encephalopathy of cirrhotics. A double‐blind, randomized trial publication-title: Ital J Gastroenterol – volume: 36 start-page: 519A year: 2002 article-title: Safety and efficacy of rifaximin in the treatment of hepatic encephalopathy in liver cirrhosis publication-title: Hepatology – volume: 38 start-page: 51 year: 2003 end-page: 8 article-title: Comparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy: results of a randomized, double‐blind, double‐dummy, controlled clinical trial publication-title: J Hepatol – year: 2004 – volume: 18 start-page: 1063 year: 1994 end-page: 8 article-title: Lactulose‐neomycin combination versus placebo in the treatment of acute hepatic encephalopathy. Results of a randomized controlled trial [in French] publication-title: Gastroenterol Clin Biol – volume: 328 start-page: 1046 year: 2004 end-page: 51 article-title: Non‐absorbable disaccharides for hepatic encephalopathy: systematic review of randomised trials publication-title: BMJ – volume: 13 start-page: 593 year: 1997 end-page: 601 article-title: Rifaximin, a non‐absorbable rifamycin, for the treatment of hepatic encephalopathy. A double‐blind, randomised trial publication-title: Curr Med Res Opin – volume: 23 start-page: 403 year: 1991 end-page: 7 article-title: Rifaximine versus neomycin in the treatment of portosystemic encephalopathy publication-title: Ital J Gastroenterol – volume: 40 start-page: 646A year: 2004 article-title: Rifaximin treatment is beneficial for mild hepatic encephalopathy publication-title: Hepatology – volume: 4 start-page: 279 year: 1984 end-page: 87 article-title: Comparison of dietary protein with an oral, branched chain‐enriched amino acid supplement in chronic portal‐systemic encephalopathy: a randomized controlled trial publication-title: Hepatology – start-page: 41 year: 2001 end-page: 2 – volume: 130 start-page: A‐806 issue: Suppl. 2 year: 2006 article-title: Is rifaximin cost‐effective in the management of hepatic encephalopathy? publication-title: Gastroenterology – volume: 50 start-page: 97 year: 2005 end-page: 106 article-title: Rifaximin – a novel antimicrobial for enteric infections publication-title: J Infect – volume: 2 start-page: 772 year: 1979 end-page: 5 article-title: Hyperammonaemia, plasma aminoacid imbalance, and blood‐brain aminoacid transport: a unified theory of portal‐systemic encephalopathy publication-title: Lancet – volume: 12 start-page: 203 year: 2000 end-page: 8 article-title: Evaluation of the efficacy and safety of rifaximin in the treatment of hepatic encephalopathy: a double‐blind, randomized, dose‐finding multi‐centre study publication-title: Eur J Gastroenterol Hepatol – volume: 13 start-page: 274 year: 1995 end-page: 81 article-title: Rifaximin in the treatment of chronic hepatic encephalopathy publication-title: Curr Med Res Opin – volume: 38 start-page: 916 year: 1993 end-page: 22 article-title: Lactitol in treatment of chronic hepatic encephalopathy. A meta‐analysis publication-title: Dig Dis Sci – volume: 39 start-page: 284 year: 2005 end-page: 9 article-title: Rifaximin: a new treatment for travelers’ diarrhea publication-title: Ann Pharmacother – volume: 13 start-page: 109 year: 1993 end-page: 18 article-title: Double‐blind, double‐dummy comparison between treatment with rifaximin and lactulose in patients with medium to severe degree hepatic encephalopathy publication-title: Curr Med Res Opin – volume: 96 start-page: 1968 year: 2001 end-page: 76 article-title: Hepatic encephalopathy publication-title: Am J Gastroenterol – volume: 1 start-page: 890 year: 1966 end-page: 2 article-title: Treatment of chronic portal‐systemic encephalopathy with lactulose publication-title: Lancet – volume: 23 start-page: 398 year: 1978 end-page: 406 – volume: 67 start-page: 1066 year: 1979 end-page: 76 article-title: Drugs, alcohol and malabsorption publication-title: Am J Med – volume: 4 start-page: 57 year: 1993 end-page: 66 article-title: Rifaximin in the treatment of hepatic encephalopathy publication-title: Eur J Clin Res – volume: 28 start-page: 374 year: 1998 end-page: 8 article-title: Flumazenil for hepatic encephalopathy grade III and IVa in patients with cirrhosis: an Italian multicenter double‐blind, placebo‐controlled, cross‐over study publication-title: Hepatology – volume: 54 start-page: 598 year: 1993 end-page: 608 article-title: Rifaximin in the treatment of chronic hepatic encephalopathy: results of a multicenter study of efficacy and safety publication-title: Curr Ther Res – volume: 39 start-page: 542 year: 1992 end-page: 5 article-title: Double‐blind randomized clinical trial comparing neomycin and placebo in the treatment of exogenous hepatic encephalopathy publication-title: Hepatogastroenterology – volume: 76 start-page: 1347 year: 1979 end-page: 51 article-title: Treatment of chronic portal systemic encephalopathy with bromocriptine: a double‐blind controlled trial publication-title: Gastroenterology – volume: 20 start-page: 159 year: 1996 end-page: 64 article-title: Overview of randomized clinical trials of oral branched‐chain amino acid treatment in chronic hepatic encephalopathy publication-title: JPEN J Parenter Enteral Nutr – volume: 46 start-page: 399 year: 2005 end-page: 407 article-title: Comparison of rifaximin and lactulose for the treatment of hepatic encephalopathy: a prospective randomized study publication-title: Yonsei Med J – volume: 28 start-page: 856 year: 1998 end-page: 64 article-title: Oral L‐ornithine‐L‐aspartate therapy of chronic hepatic encephalopathy: results of a placebo‐controlled double‐blind study publication-title: J Hepatol – volume: 96 start-page: 623 year: 2003 end-page: 33 article-title: The neurology of liver failure publication-title: Q J Med – volume: 65 start-page: 413 year: 2004 end-page: 22 article-title: Clinical effects of rifaximin in patients with hepatic encephalopathy intolerant or nonresponsive to previous lactulose treatment: an open‐label pilot study publication-title: Curr Ther Res Clin Exp – volume: 11 start-page: 7197 year: 2005 end-page: 202 article-title: Effects of L‐carnitine in patients with hepatic encephalopathy publication-title: World J Gastroenterol – volume: 25 start-page: 1351 year: 1997 end-page: 60 article-title: Therapeutic efficacy of L‐ornithine‐L‐aspartate infusions in patients with cirrhosis and hepatic encephalopathy: results of a placebo‐controlled, double‐blind study publication-title: Hepatology – volume: 337 start-page: 473 year: 1997 end-page: 9 article-title: Treatment of hepatic encephalopathy publication-title: N Engl J Med – volume: 4 start-page: 7 year: 1993 end-page: 18 article-title: Treatment of hepatic encephalopathy with rifaximin: double blind, double dummy study versus lactulose publication-title: Eur J Clin Res – ident: e_1_2_8_53_2 doi: 10.1016/S0168-8278(98)80237-7 – ident: e_1_2_8_24_2 doi: 10.1016/S0011-393X(05)80681-2 – ident: e_1_2_8_22_2 doi: 10.1345/aph.1E407 – ident: e_1_2_8_2_2 doi: 10.3810/pgm.2001.02.850 – ident: e_1_2_8_7_2 doi: 10.1016/S0168-8278(99)80144-5 – ident: e_1_2_8_56_2 doi: 10.1007/978-1-4684-5826-8_13 – ident: e_1_2_8_16_2 doi: 10.1136/gut.23.1.1 – volume: 76 start-page: 1347 year: 1979 ident: e_1_2_8_50_2 article-title: Treatment of chronic portal systemic encephalopathy with bromocriptine: a double‐blind controlled trial publication-title: Gastroenterology doi: 10.1016/0016-5085(79)90399-8 contributor: fullname: Uribe M – ident: e_1_2_8_28_2 doi: 10.1185/03007999309111539 – volume: 4 start-page: 57 year: 1993 ident: e_1_2_8_30_2 article-title: Rifaximin in the treatment of hepatic encephalopathy publication-title: Eur J Clin Res contributor: fullname: Giacomo F – ident: e_1_2_8_40_2 doi: 10.3349/ymj.2005.46.3.399 – ident: e_1_2_8_36_2 doi: 10.1016/S0011-393X(05)80433-3 – ident: e_1_2_8_52_2 doi: 10.1002/hep.510250609 – volume: 1 start-page: 890 year: 1966 ident: e_1_2_8_12_2 article-title: Treatment of chronic portal‐systemic encephalopathy with lactulose publication-title: Lancet contributor: fullname: Bircher J – ident: e_1_2_8_11_2 doi: 10.1007/BF01295920 – ident: e_1_2_8_8_2 doi: 10.1056/NEJM199708143370707 – volume-title: Xifaxan [package insert] year: 2005 ident: e_1_2_8_21_2 – volume-title: Levocarnitine [package insert] year: 2004 ident: e_1_2_8_54_2 – ident: e_1_2_8_20_2 doi: 10.1128/AAC.44.8.2205-2206.2000 – ident: e_1_2_8_19_2 doi: 10.3109/00365528708991867 – ident: e_1_2_8_44_2 doi: 10.1016/0168-8278(90)90103-X – volume: 23 start-page: 175 year: 1991 ident: e_1_2_8_31_2 article-title: Rifaximin versus neomycin on hyperammoniemia in chronic portal systemic encephalopathy of cirrhotics. A double‐blind, randomized trial publication-title: Ital J Gastroenterol contributor: fullname: Pedretti G – ident: e_1_2_8_47_2 doi: 10.1002/hep.1840040218 – ident: e_1_2_8_17_2 doi: 10.1007/978-1-4615-1989-8_13 – ident: e_1_2_8_55_2 doi: 10.3748/wjg.v11.i45.7197 – ident: e_1_2_8_5_2 – ident: e_1_2_8_18_2 doi: 10.1016/0002-9343(79)90649-1 – ident: e_1_2_8_33_2 doi: 10.1185/03007999709113333 – ident: e_1_2_8_6_2 doi: 10.1093/qjmed/hcg110 – ident: e_1_2_8_43_2 doi: 10.1002/hep.1840160123 – ident: e_1_2_8_41_2 article-title: Hospitalizations during the use of rifaximin versus lactulose for the treatment of hepatic encephalopathy publication-title: Dig Dis Sci contributor: fullname: Leevy CB – volume: 4 start-page: 7 year: 1993 ident: e_1_2_8_29_2 article-title: Treatment of hepatic encephalopathy with rifaximin: double blind, double dummy study versus lactulose publication-title: Eur J Clin Res contributor: fullname: Massa P – volume: 91 start-page: 1266 year: 1996 ident: e_1_2_8_46_2 article-title: Severe recurrent hepatic encephalopathy that responded to oral branched chain amino acids publication-title: Am J Gastroenterol contributor: fullname: Chalasani N – ident: e_1_2_8_57_2 doi: 10.1016/S1542-3565(04)00667-6 – volume: 130 start-page: A‐806 issue: 2 year: 2006 ident: e_1_2_8_42_2 article-title: Is rifaximin cost‐effective in the management of hepatic encephalopathy? publication-title: Gastroenterology contributor: fullname: Spiegel BM – volume: 23 start-page: 403 year: 1991 ident: e_1_2_8_32_2 article-title: Rifaximine versus neomycin in the treatment of portosystemic encephalopathy publication-title: Ital J Gastroenterol contributor: fullname: Di Piazza S – ident: e_1_2_8_26_2 doi: 10.1185/03007999509111552 – ident: e_1_2_8_49_2 doi: 10.1177/0148607196020002159 – ident: e_1_2_8_27_2 doi: 10.1016/S0168-8278(02)00350-1 – volume: 11 start-page: 387 year: 1985 ident: e_1_2_8_34_2 article-title: A non‐absorbable rifamycin for treatment of hepatic encephalopathy publication-title: Drugs Exp Clin Res contributor: fullname: Testa R – volume: 39 start-page: 542 year: 1992 ident: e_1_2_8_14_2 article-title: Double‐blind randomized clinical trial comparing neomycin and placebo in the treatment of exogenous hepatic encephalopathy publication-title: Hepatogastroenterology contributor: fullname: Strauss E – volume: 49 start-page: 53 year: 2003 ident: e_1_2_8_38_2 article-title: Cyclic treatment of chronic hepatic encephalopathy with rifaximin: results of a double‐blind clinical study publication-title: Minerva Gastroenterol Dietol contributor: fullname: Loguercio C – start-page: 398 volume-title: Am J Dig Dis year: 1978 ident: e_1_2_8_10_2 contributor: fullname: Atterbury CE – ident: e_1_2_8_13_2 doi: 10.1136/bmj.38048.506134.EE – volume: 18 start-page: 1063 year: 1994 ident: e_1_2_8_15_2 article-title: Lactulose‐neomycin combination versus placebo in the treatment of acute hepatic encephalopathy. Results of a randomized controlled trial [in French] publication-title: Gastroenterol Clin Biol contributor: fullname: Blanc P – volume: 72 start-page: 573 year: 1977 ident: e_1_2_8_9_2 article-title: Comparison of lactulose and neomycin in the treatment of chronic portal‐systemic encephalopathy publication-title: Gastroenterology doi: 10.1016/S0016-5085(77)80135-2 contributor: fullname: Conn HO – ident: e_1_2_8_48_2 doi: 10.1016/0016-5085(89)91517-5 – ident: e_1_2_8_45_2 doi: 10.1016/S0140-6736(79)92119-6 – ident: e_1_2_8_23_2 doi: 10.1016/j.jinf.2004.05.019 – ident: e_1_2_8_3_2 doi: 10.1111/j.1572-0241.2001.03964.x – volume: 40 start-page: 646A year: 2004 ident: e_1_2_8_4_2 article-title: Rifaximin treatment is beneficial for mild hepatic encephalopathy publication-title: Hepatology contributor: fullname: Bass NM – ident: e_1_2_8_37_2 doi: 10.1016/j.curtheres.2004.10.002 – ident: e_1_2_8_25_2 doi: 10.1097/00042737-200012020-00012 – volume: 36 start-page: 668 year: 1984 ident: e_1_2_8_35_2 article-title: Rifaximin in collateral treatment of portal‐systemic encephalopathy: a preliminary report publication-title: Curr Ther Res Clin Exp contributor: fullname: De Marco F – ident: e_1_2_8_51_2 doi: 10.1002/hep.510280212 – volume: 36 start-page: 519A year: 2002 ident: e_1_2_8_39_2 article-title: Safety and efficacy of rifaximin in the treatment of hepatic encephalopathy in liver cirrhosis publication-title: Hepatology contributor: fullname: Lata J |
| SSID | ssj0006702 |
| Score | 2.1824596 |
| SecondaryResourceType | review_article |
| Snippet | Effective treatment options for hepatic encephalopathy are limited. Based on the principle that intestinal‐derived ammonia contributes to the pathogenesis of... Effective treatment options for hepatic encephalopathy are limited. Based on the principle that intestinal-derived ammonia contributes to the pathogenesis of... AbstractEffective treatment options for hepatic encephalopathy are limited. Based on the principle that intestinal-derived ammonia contributes to the... |
| SourceID | proquest crossref pubmed wiley |
| SourceType | Aggregation Database Index Database Publisher |
| StartPage | 23 |
| SubjectTerms | Anti-Bacterial Agents - therapeutic use Female Hepatic Encephalopathy - drug therapy Hepatic Encephalopathy - economics Humans Male Rifamycins - therapeutic use |
| Title | Review article: the current pharmacological therapies for hepatic encephalopathy |
| URI | https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fj.1746-6342.2006.03218.x https://www.ncbi.nlm.nih.gov/pubmed/17295849 https://search.proquest.com/docview/20440507 https://search.proquest.com/docview/69003436 |
| Volume | 25 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1ZSwMxEB6kgvjifdQzD75u6W6yya5v9SgiKCIt9G1J0ixCZSvagvrrndlsrfUAEd92IXskM5P55sgMwBGKDHVESgON6ioQNgkDY2QzsFpIYXnaF006jXx1LS-64rIX96r8JzoL4-tDvDvcSDLK_ZoEXJunWSFXQgaSi6iKKXBUVw3CkyFXlN13djutJCVVmX6IFkcaREnIPyf1fPOiWU31BX7OotlSHbWXYTCZiM9CGTTGI9Owr59qPP7PTFdgqUKtrOXZbBXmXLEGC1dVXH4dbnyIgVV8eMwQVjLrSz-xh2l1bOII5o98oYXOEDCzO0c53ZbRDoMj74fUI_llA7rt887pRVD1agiQoChs3Ko0tlrFuZaxi8O-SBOntI4R4UltEcRogXtZrBSa42Qj5VLoFLGMUQhCjOObUCuGhdsGhpBVmNxYnhNcchHeKSRbnvNI2USaOoQTumQPviRH9sGUwaXKaKmowabMyqXKnutwOCFghvJDQRFduOH4CUcJxKxN9fMISc5ewWUdtjzlp19FywQBXFoHWdLv17-TtW46dLXz1wd3YdE7mSmvZg9qo8ex20d0NDIHMN86OTtpH5T8_waYyACw |
| link.rule.ids | 314,780,784,1375,27924,27925,46294,46718 |
| linkProvider | Wiley-Blackwell |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1ZSwMxEB5EQX3xPuqZB1-3dDfZZNc3UUs9KiIt9G1J0iyC0oq2oP56ZzZbaz1AxLddyB7J5Eu-OTIDcICQoYpIaaBxuwqETcLAGFkLrBZSWJ52RY1OIzevZKMtzjtxpywHRGdhfH6Id4MbIaNYrwngZJCeRLkSMpBcRKVTgeN-VUVCOYPoDym-6-RmnEtKqiIAEXWONIiSkH8O6_nmTZN71RcCOslniw2pvgj3o674OJS76nBgqvb1U5bHf-rrEiyUxJUd-Zm2DFOutwKzzdI1vwrX3svAyql4yJBZMuuzP7GHcYJsmhTMn_pCJZ0hZ2a3jsK6LaNFBlve96lM8ssatOunreNGUJZrCFCmiDduVRpbreJcy9jFYVekiVNax0jypLbIY7TA5SxWCjVyUpNyKXSKdMYo5CHG8XWY7vV7bhMYslZhcmN5TozJRXinUG55ziNlE2kqEI4Ekz34rBzZB20GhyqjoaIamzIrhip7rsD-SIIZQoj8Irrn-sMnbCWQttbUzy0k2XsFlxXY8KIffxWVE-RwaQVkIcBf_052dN2iq62_PrgPc41W8zK7PLu62IZ5b3OmMJsdmB48Dt0ukqWB2StA8AazwQNf |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrZ1LSwMxEIAHUShefD_qqzl43dI22WTXm1hLfbQUUehtSdIsgtIWbUH99c5sttZWBRFve8i-Mpnkm8xkBuAYVYYqIsWBxuUqEDaqBsbISmC1kMLyuCcqdBq51ZbNO3HZDbt5_BOdhfH5IT423EgzsvmaFHzYS2eVXAkZSC5quU-B43JVRp5cErIWUx79-s00lZRUWfwhmhxxUIuqfD6q55snzS5VX_hzFmez9aixCg-TP_FhKA_l8ciU7dtcksf_-dU1WMmxlZ36cbYOC66_AYVW7pjfhI73MbB8IJ4w5Epmfe4nNpymx6YhwfyZLzTRGRIzu3cU1G0ZTTHY8nFARZJft-CucX571gzyYg0BShS1jVsVh1arMNUydGG1J-LIKa1DRDypLVKMFjiZhUqhPU5GUiqFjhFmjEIKMY5vw2J_0He7wJBZhUmN5SnxkkNZGoViS1NeUzaSpgjViVySoc_JkXyyZbCrEuoqqrApk6yrkpcilCYCTFCByCui-24wfsZWAqG1on5uIWm3V3BZhB0v-elb0TRBgouLIDP5_fpzktPOLV3t_fXGEhQ69UZyfdG-2odlv-FMMTYHsDh6GrtDJKWROcpU4B2T_QIO |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Review+article%3A+the+current+pharmacological+therapies+for+hepatic+encephalopathy&rft.jtitle=Alimentary+pharmacology+%26+therapeutics&rft.au=Bass%2C+N+M&rft.date=2007-02-01&rft.issn=0269-2813&rft.volume=25+Suppl+1&rft.spage=23&rft.epage=31&rft_id=info:doi/10.1111%2Fj.1746-6342.2006.03218.x&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0269-2813&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0269-2813&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0269-2813&client=summon |